Search
Now showing items 1-10 of 34
Syntheses of sulfanylphthalimide and xanthine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of adenosine receptors
(North-West University, 2013)
Currently L-DOPA is the drug most commonly used for the treatment of Parkinson’s disease (PD). However, the long-term use of L-DOPA is associated with the development of motor fluctuations and dyskinesias. Treatment mainly ...
Syntheses of chalcones and 2–aminopyrimidines and their evaluation as monoamine oxidase inhibitors and as adenosine receptor antagonists
(North-West University, 2013)
Background and rationale - Parkinson’s disease is a neurodegenerative disorder characterised by reduced levels of
dopamine in the brain. The cause of Parkinson's disease is still unknown; however several theories pertaining ...
Inhibition of monoamine oxidase by caffeine– and phthalide analogues
(North-West University, 2012)
Monoamine oxidase (MAO) consists of two isoforms, MAO-A and MAO-B. MAO is responsible for the oxidation of neurotransmitter and dietary amines. The MAO-B isoform, in particular, is considered to be a drug target for the ...
Design and synthesis of heterocyclic compounds for neuroprotective enzyme interactions
(North-West University, 2010)
Neurodegenerative diseases are thought to be multifactorial in nature and therefore
current research focus has shifted from a ‘one-drug-one-target’ approach to that of multitarget directed ligands (MTDLs). These ligands ...
Inhibition of monoamine oxidase B by substituted coumarin derivatives
(North-West University, 2008)
Interest in the selective inhibition of monoamine oxidase B (MAO-B) has increased in the last years due to their therapeutic potential in age related neurodegenerative diseases such as Alzheimer's disease and Parkinson's ...
The preparation and evaluation of xanthinyl analogues as inhibitors of monoamine oxidase B
(North-West University, 2006)
Monoamine oxidase B (MAO-B) is a drug target for the treatment of neurodegenerative diseases such as Parkinson's disease. For example, the mechanism-based inactivator of MAO-B,
(R)-deprenyl, is frequently used in combination ...
Identification of monoamine oxidase inhibitors using a molecular modelling approach
(2014)
Monoamine oxidase (MAO) is an enzyme located on the outer mitochondrial membrane and is considered to be a target for the treatment of diseases such as Parkinson’s disease and depression. MAO may be classified into two ...
Monoamine oxidase inhibitory activities of heterocyclic chalcones
(2013)
Parkinson’s disease is the second most common age-related neurodegenerative disease after Alzheimer’s disease. The characteristic pathological feature of Parkinson’s disease is the loss of neurons in the substantia nigra ...
Monoamine oxidase inhibition by novel quinolinones
(2014)
Parkinson’s disease (PD) is an age-related neurodegenerative disorder. The degeneration of the neurons of the substantia nigra in the midbrain leads to the loss of dopamine from the striatum, which
is responsible for the ...
Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase
(2014)
BACKGROUND AND RATIONALE
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder affecting the central nervous system, primarily, the substantia nigra. It is characterized by loss of dopaminergic ...